₹342.3
-0.12% today
· 30d -7.65%
as of 2026-09-04
Price · Daily Candles
“FDC Pharma's Net Profit Plummets 23.59% YoY; FIIs Edge Up Stake Amidst Sluggish Growth.”
FDC Limited, a ~₹6564 Cr pharmaceutical company, displayed a challenging Q4 2025 with net profit declining by 23.59% YoY despite a 0.13% revenue increase. While the annual revenue for FY25 grew by 3.11%, net profit fell by 12.59%. Its TTM PE ratio of 30.31 suggests it's more expensive than some peers and its intrinsic value analysis signals it as overvalued by 58.7%.
BULL CASE
+Operational performance shows strength as quarterly operating profit grew by 11.6% YoY to ₹73 Cr, with OPM improving by 1.49%.
+FIIs increased their stake by 0.08% QoQ, holding 2.4% of the company as of March 31, 2026.
+The stock has shown strong short-term upward momentum, with a 1-day return of 8.83% and a 1-week return of 10.33%.
+ML predictions indicate a neutral to strong rank for 1-year EBIT growth across various lookback periods (0.538 to 0.609).
BEAR CASE
−Net profit saw a significant decline of 23.59% YoY in the last quarter to ₹28 Cr, and annual net profit for FY25 decreased by 12.59% YoY.
−The stock is trading at a TTM PE of 30.31, higher than the sector median among peers like Dr. Reddy's (19.55) and Zydus Life (21.54).
−Over the past year, the stock has underperformed, registering a -11.94% return.
−The intrinsic value analysis suggests the stock is overvalued by 58.7% with an intrinsic value per share of ₹165.68 against a current price of ₹401.6.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-03-31
REVENUE
₹585 Cr
+18.89% YoY
NET PROFIT
₹103 Cr
+167.37% YoY
OPM
24.62%
+10.83pp YoY
EPS
₹6.35
PE 30.31
Intrinsic value · DCF: N/A — ML model predicts severe Δ FCF compression (h1=-27.0%, h2=-33.1%, h3=-32.7% of mktcap), driving projected FCF negative by year 3 despite healthy current FCF. Treating as forecast outlier rather than reporting a misleading ₹0 valuation. Use the Strategy Fit and ML sections instead.
◇ Sector Position
FDC's TTM PE of 30.31 sits above peers like Dr. Reddy's (19.55) and Zydus Life (21.54), while its ROCE of 16.0% trails the sector leader Cipla (25.09).
PEERPEROCE %
FDC30.3116.0
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒
54
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
UNDERPERFORMER
20
Valuation
FAIR
40
Growth
STEADY
54
Profitability
HIGH
78
Technicals
WEAK
40
Risk
LOW
90
Key Stats
TTM PE
30.31
P/B
2.69
52W HIGH
₹527.8
OFF HIGH
-35.15%
DIV YIELD
2.71%
MKT CAP
₹5594 Cr
◉ Active Signals
MACDNeutral1.4063
RSI(14)Bearish34.5
Near 52W LowBearish9.38
⧉ Strategy Fit 🔒